ANTI-NEUROTENSIN ANTIBODIES AND USES THEREOF

(19)

(11)

EP 3 149 039 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	01.04.2020 Bulletin 2020/14

(45)	Mention of the grant of the patent:
	12.02.2020 Bulletin 2020/07

(21)	Application number: 15729772.2

(22)	Date of filing: 01.06.2015

(51)

International Patent Classification (IPC):

C07K 16/26^(2006.01)
A61K 39/395^(2006.01)
A61K 45/06^(2006.01)

A61K 33/24^(2019.01)
A61K 39/00^(2006.01)

(86)	International application number:
	PCT/EP2015/062168

(87)	International publication number:
	WO 2015/185513 (10.12.2015 Gazette 2015/49)

(54)	ANTI-NEUROTENSIN ANTIBODIES AND USES THEREOF ANTI-NEUROTENSIN-ANTIKÖRPER UND VERWENDUNGEN DAVON ANTICORPS ANTI-NEUROTENSINE ET LEURS UTILISATIONS

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

02.06.2014 EP 14305825

(43)	Date of publication of application:
	05.04.2017 Bulletin 2017/14

(73)	Proprietors:
	INSERM (Institut National de la Santé et de la Recherche Médicale) 75013 Paris (FR) Université de Paris 75006 Paris 6 (FR)

(72)	Inventor:
	FORGEZ, Patricia F-75270 Paris Cedex 06 (FR)

(74)	Representative: Inserm Transfert
	7, rue Watt 75013 Paris 75013 Paris (FR)

(56)

References cited: :

WO-A1-2010/069929

WINKLER K ET AL: "Changing the antigen binding specificity by single point mutations of an anti-p24 (HIV-1) antibody", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 165, no. 8, 15 October 2000 (2000-10-15), pages 4505-4514, XP002579393, ISSN: 0022-1767
MCKAY BROWN ET AL: "Tolerance to single, but not multiple, amino acid replacements in antibody V-H CDR2: A means of minimizing B cell wastage from somatic hypermutation?", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 156, no. 9, 1 January 1996 (1996-01-01), pages 3285-3291, XP002649029, ISSN: 0022-1767
MAYNARD JENNIFER A ET AL: "Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 20, no. 6, 1 June 2002 (2002-06-01), pages 597-601, XP002390004, ISSN: 1087-0156, DOI: 10.1038/NBT0602-597
BARDERAS RODRIGO ET AL: "Affinity maturation of antibodies assisted by in silico modeling", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 105, no. 26, 1 July 2008 (2008-07-01) , pages 9029-9034, XP002592575, ISSN: 0027-8424, DOI: 10.1073/PNAS.0801221105 [retrieved on 2008-06-23]
RAIEES ANDRABI ET AL: "Cross-neutralizing activity of human anti-V3 monoclonal antibodies derived from non-B clade HIV-1 infected individuals", VIROLOGY, vol. 439, no. 2, 1 May 2013 (2013-05-01), pages 81-88, XP055093156, ISSN: 0042-6822, DOI: 10.1016/j.virol.2012.12.010
CARRAWAY R E ET AL: "Involvement of neurotensin in cancer growth: Evidence, mechanisms and development of diagnostic tools", PEPTIDES, ELSEVIER, AMSTERDAM, NL, vol. 27, no. 10, 1 October 2006 (2006-10-01), pages 2445-2460, XP027957619, ISSN: 0196-9781 [retrieved on 2006-10-01]

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).